Table 2.
Changes in BMD
| Parameter | Study treatment | |||||
|---|---|---|---|---|---|---|
| Control (n = 16) | SrRan (n = 16) | SrRan + AD3 (n = 16) | ||||
| Pre-therapy | Post-therapy | Pre-therapy | Post-therapy | Pre-therapy | Post-therapy | |
| Spine | ||||||
| BMD (g/cm2, mean ± SD) | 0.741 ± 0.02 | 0.742 ± 0.01 | 0.746 ± 0.01 | 0.780 ± 0.01 | 0.749 ± 0.01 | 0.810 ± 0.01 |
| P = 0.45 | P = 0.04 | P < 0.0001 | ||||
| P c = 0.03 | P c < 0.001 | |||||
| P SR = 0.03 | ||||||
| % Change (↓ ↑) (mean ± SD) | ↑ 0.24 ± 0.45 | ↑ 4.65 ± 0.56 | ↑ 8.18 ± 0.62 | |||
| Median (IQR) | 0.11 (−1.43 to 1.40) | 4.78 (2.59–5.67) | 8.54 (6.22–9.99) | |||
| Collum femoris | ||||||
| BMD (g/cm2, mean ± SD) | 0.780 ± 0.01 | 0.781 ± 0.01 | 0.780 ± 0.003 | 0.805 ± 0.01 | 0.799 ± 0.02 | 0.862 ± 0.02 |
| P = 0.41 | P < 0.0001 | P = 0.01 | ||||
| P c = 0.02 | P c = 0.01 | |||||
| P SR = 0.01 | ||||||
| % Change (↓ ↑) (mean ± SD) | ↑ 0.06 ± 0.02 | ↑ 3.20 ± 0.46 | ↑ 8.17 ± 1.44 | |||
| Median (IQR) | 0.12 (0.0001–0.13) | 2.87 (1.91–3.42) | 6.10 (4.97–9.38) | |||
AD 3 alfacalcidol, BMD bone mineral density, IQR interquartile range (25th–75th percentiles), P in relation to the parameter before therapy, P c in relation to the parameter in the control group, P SR in relation to the parameter in SrRan group after therapy, SD standard deviation, SrRan strontium ranelate